Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Aurora, CO
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Hartford, CT
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Washington,
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Gainesville, GA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
New Orleans, LA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Baltimore, MD
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Boston, MA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Rochester, MN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
St Louis, MO
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
St Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Omaha, NE
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Brick, NJ
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Albuquerque, NM
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Mineola, NY
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
High Point, NC
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
High Point, NC
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Bismark, ND
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis
mi
from
Portland, OR
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Blue Bell, PA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)
Status: Enrolling
Updated:  12/13/2012
Mission Internal Medical Group
mi
from
Mission Viejo, CA
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors
Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)
Status: Enrolling
Updated: 12/13/2012
Mission Internal Medical Group
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Analysis of the Impact of Using a Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Status: Enrolling
Updated:  12/14/2012
Wayne State University
mi
from
Detroit, MI
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Analysis of the Impact of Using a Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
Status: Enrolling
Updated: 12/14/2012
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated:  12/17/2012
St Marys Hospital
mi
from
Rochester, MN
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated: 12/17/2012
St Marys Hospital
mi
from
Rochester, MN
Click here to add this to my saved trials
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated:  12/17/2012
Rochester Methodist Hospital
mi
from
Rochester, MN
Coronary Disease Morbidity and Mortality in a Population
Coronary Disease Morbidity and Mortality in a Population
Status: Enrolling
Updated: 12/17/2012
Rochester Methodist Hospital
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated:  12/18/2012
Novartis Investigative Site
mi
from
Mineola, NY
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated: 12/18/2012
Novartis Investigative Site
mi
from
Mineola, NY
Click here to add this to my saved trials
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated:  12/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients
A Multi Center, Randomized , Double Blind, Placebo-controlled, Study of the Safety, Tolerability, and Effects on Arterial Structure and Function of ACZ885 in Patients With Clinically Evident Atherosclerosis and Either T2DM or IGT
Status: Enrolling
Updated: 12/18/2012
Novartis Investigative Site
mi
from
Cincinatti, OH
Click here to add this to my saved trials
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V
Status: Enrolling
Updated:  12/20/2012
Scripps Green Hospital/Scripps Clinic
mi
from
La Jolla, CA
SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents
Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents. Short Title: Scripps V
Status: Enrolling
Updated: 12/20/2012
Scripps Green Hospital/Scripps Clinic
mi
from
La Jolla, CA
Click here to add this to my saved trials
Effect of GLP-1 on Postprandial Lipid Metabolism
The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery
Status: Enrolling
Updated:  1/2/2013
Veteran's Affairs Clinical Research Unit
mi
from
Cincinnati, OH
Effect of GLP-1 on Postprandial Lipid Metabolism
The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery
Status: Enrolling
Updated: 1/2/2013
Veteran's Affairs Clinical Research Unit
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Status: Enrolling
Updated:  1/4/2013
Department of Anesthesia and Perioperative Care
mi
from
San Fransisco, CA
Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Phase 2 Study of Effect of Xenon, in Combination With Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Status: Enrolling
Updated: 1/4/2013
Department of Anesthesia and Perioperative Care
mi
from
San Fransisco, CA
Click here to add this to my saved trials
Cognitive Dysfunction in Postural Tachycardia Syndrome
Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)
Status: Enrolling
Updated:  1/7/2013
Vanderbilt University
mi
from
Nashville, TN
Cognitive Dysfunction in Postural Tachycardia Syndrome
Origins of Cognitive Dysfunction in Postural Tachycardia Syndrome (POTS)
Status: Enrolling
Updated: 1/7/2013
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Morehouse School of Medicine
mi
from
Atlanta, GA
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Morehouse School of Medicine
mi
from
Atlanta, GA
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Harvard University
mi
from
Cambridge, MA
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Harvard University
mi
from
Cambridge, MA
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
Baylor College of Medicine
mi
from
Houston, TX
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated:  1/8/2013
University of Vermont
mi
from
Burlington, VT
Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Status: Enrolling
Updated: 1/8/2013
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated:  1/8/2013
Heart & Vascular Center of Arizona
mi
from
Phoenix, AZ
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated: 1/8/2013
Heart & Vascular Center of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated:  1/8/2013
UCLA Medical Center
mi
from
Los Angeles, CA
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated: 1/8/2013
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated:  1/8/2013
Tufts Medical Center
mi
from
Boston, MA
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated: 1/8/2013
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated:  1/8/2013
Columbia University Medical Center
mi
from
New York, NY
Cardiox Shunt Detection Technology Study
FDS-0004 Cardiox Shunt Detection Technology Study
Status: Enrolling
Updated: 1/8/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials